Cargando…

Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT(6) Receptor Partial Agonist and Dopamine Transporter Inhibitor

Since 5-HT(6) receptors play role in controlling feeding and satiety and dopamine is essential for normal feeding behavior, we evaluated the ability of EMD 386088—5-HT(6) receptor partial agonist and dopamine transporter inhibitor—to reduce body weight in obese rats, as well as its anorectic propert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotańska, Magdalena, Śniecikowska, Joanna, Jastrzębska-Więsek, Magdalena, Kołaczkowski, Marcin, Pytka, Karolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296348/ https://www.ncbi.nlm.nih.gov/pubmed/28228713 http://dx.doi.org/10.3389/fnins.2017.00050

Ejemplares similares

Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT(6) partial agonist in rats
por: Jastrzębska-Więsek, Magdalena, et al.
Publicado: (2016)

Study on the effect of EMD386088, a 5-HT(6) receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats
por: Jastrzębska-Więsek, Magdalena, et al.
Publicado: (2017)

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT(1A) Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile
por: Sniecikowska, Joanna, et al.
Publicado: (2020)

Idalopirdine, a selective 5-HT(6) receptor antagonist, reduces food intake and body weight in a model of excessive eating
por: Kotańska, Magdalena, et al.
Publicado: (2018)

The selective 5-HT(1A) receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress
por: Głuch-Lutwin, Monika, et al.
Publicado: (2021)

Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT(1A) receptor partial agonists
por: Partyka, Anna, et al.
Publicado: (2020)

EMD386088 (5 mg/kg) has no effect on latent inhibition shown to both light and noise stimuli
por: Cassaday, Helen Joan, et al.
Publicado: (2019)

ADN-1184, a monoaminergic ligand with 5-HT(6/7) receptor antagonist action, exhibits activity in animal models of anxiety
por: Partyka, Anna, et al.
Publicado: (2016)

Single Administration of HBK-15—a Triple 5-HT(1A), 5-HT(7), and 5-HT(3) Receptor Antagonist—Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone
por: Pytka, Karolina, et al.
Publicado: (2017)

Selective 5-HT(6) Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats
por: Partyka, Anna, et al.
Publicado: (2023)

Dual Molecules Targeting 5-HT(6) and GABA-A Receptors as a New Approach to Combat Depression Associated with Neuroinflammation
por: Marcinkowska, Monika, et al.
Publicado: (2023)

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia
por: Marcinkowska, Monika, et al.
Publicado: (2021)

Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT(1A) and 5-HT(7) Antagonists in Animal Models
por: Pytka, Karolina, et al.
Publicado: (2015)

HBK-15, a Multimodal Compound, Showed an Anxiolytic-Like Effect in Rats
por: Lustyk, Klaudia, et al.
Publicado: (2022)

The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT(6) Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment
por: Latacz, Gniewomir, et al.
Publicado: (2019)

The Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia
por: Jastrzębska-Więsek, Magdalena, et al.
Publicado: (2022)

HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

Effect of 5-HT(6) Receptor Ligands Combined with Haloperidol or Risperidone on Antidepressant-/Anxiolytic-Like Behavior and BDNF Regulation in Hippocampus and Prefrontal Cortex of Rats
por: Wesołowska, Anna, et al.
Publicado: (2021)

Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents
por: Marcinkowska, Monika, et al.
Publicado: (2018)

Are the Hydantoin-1,3,5-triazine 5-HT(6)R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro
por: Lubelska, Annamaria, et al.
Publicado: (2019)

Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α(2)-adrenoceptor and trace amine-associated receptor 1 ligand
por: Kotańska, Magdalena, et al.
Publicado: (2023)

Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT(6) Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo
por: Kurczab, Rafał, et al.
Publicado: (2018)

Chemically Homogenous Compounds with Antagonistic Properties at All α(1)-Adrenoceptor Subtypes but not β(1)-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

Idalopirdine – a small molecule antagonist of 5-HT(6) with therapeutic potential against obesity
por: Dudek, Magdalena, et al.
Publicado: (2015)

Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates
por: Marcinkowska, Monika, et al.
Publicado: (2020)

Serotonin 5-HT(6) Receptor Ligands and Butyrylcholinesterase Inhibitors Displaying Antioxidant Activity—Design, Synthesis and Biological Evaluation of Multifunctional Agents against Alzheimer’s Disease
por: Więckowski, Krzysztof, et al.
Publicado: (2022)

HBK-17, a 5-HT(1A) Receptor Ligand With Anxiolytic-Like Activity, Preferentially Activates ß-Arrestin Signaling
por: Pytka, Karolina, et al.
Publicado: (2018)

Novel and effective synthesis protocol of AgNPs functionalized using L-cysteine as a potential drug carrier
por: Wojnicki, Marek, et al.
Publicado: (2017)

H(3) histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice
por: Dudek, Magdalena, et al.
Publicado: (2016)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
por: Mohr, Pavel, et al.
Publicado: (2022)

The Phenoxyalkyltriazine Antagonists for 5-HT(6) Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases
por: Sudoł, Sylwia, et al.
Publicado: (2021)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Repeated Clozapine Increases the Level of Serotonin 5-HT(1A)R Heterodimerization with 5-HT(2A) or Dopamine D(2) Receptors in the Mouse Cortex
por: Szlachta, Marta, et al.
Publicado: (2018)

Potential Anti-Amnesic Activity of a Novel Multimodal Derivative of Salicylamide, JJGW08, in Mice
por: Żmudzka, Elżbieta, et al.
Publicado: (2023)

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Novel Multimodal Salicylamide Derivative with Antidepressant-like, Anxiolytic-like, Antipsychotic-like, and Anti-Amnesic Activity in Mice
por: Żmudzka, Elżbieta, et al.
Publicado: (2023)

The histamine H(3) receptor inverse agonist pitolisant reduces body weight in obese mice
por: Kotańska, Magdalena, et al.
Publicado: (2018)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT(1A) Receptor Partial Agonist/5-HT(6) Receptor Full Agonist
por: Liu, Wen-Gang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4tafejpp8oi33enor0a45h5nts